Eli Lilly’s stock tumbles as Mounjaro, Zepbound sales miss by wide margins
Eli Lilly’s stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly’s stock heads for biggest selloff since 2008 after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
